LeMaitre Vascular (NASDAQ: LMAT) insider details dividend rights release

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. reported insider equity transactions by its president and director dated 12/11/2025 and 12/12/2025. The reporting person acquired small amounts of common stock at $0 per share through the release of dividend equivalent rights tied to earlier restricted and performance stock unit awards. On those same dates, the issuer withheld 297 and 302 shares on multiple transactions to cover tax withholding obligations triggered by the vesting of awards granted on 12/11/2021 and 12/12/2022. After all reported activity, the insider directly owned 22,251 shares of LeMaitre Vascular common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Director

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		25(1)	A	$0(1)	23,116	D
Common Stock	12/11/2025		F		297(2)	D	$83.36	22,819	D
Common Stock	12/12/2025		M		18(1)	A	$0(1)	22,837	D
Common Stock	12/12/2025		F		302(3)	D	$84	22,535	D
Common Stock	12/12/2025		M		18(1)	A	$0(1)	22,553	D
Common Stock	12/12/2025		F		302(4)	D	$84	22,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(5)	12/11/2025		M			25(5)	(5)	(5)	Common Stock	25	$0	0(6)	D
Dividend Equivalent Rights	(7)	12/12/2025		M			18(7)	(7)	(7)	Common Stock	18	$0	19.974	D
Dividend Equivalent Rights	(8)	12/12/2025		M			18(8)	(8)	(8)	Common Stock	18	$0	19.291	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/11/2021. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

3. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

4. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

5. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.

7. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

8. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did LeMaitre Vascular (LMAT) report in this Form 4?

The filing shows a LeMaitre Vascular president and director acquiring small amounts of common stock via released dividend equivalent rights and having shares withheld to cover taxes on vesting equity awards on 12/11/2025 and 12/12/2025.

How many LMAT shares does the insider own after these transactions?

Following the reported transactions, the insider directly owned 22,251 shares of LeMaitre Vascular common stock.

Why were 297 and 302 LMAT shares withheld from the insider?

The filing states that 297 shares on 12/11/2025 and 302 shares on 12/12/2025 in two separate transactions were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units and performance stock units awarded in 2021 and 2022.

What are dividend equivalent rights in this LMAT insider report?

The document explains that the reported dividend equivalent rights are each the economic equivalent of one share of LeMaitre Vascular common stock and were released in connection with the vesting of prior restricted stock unit and performance stock unit awards.

What derivative securities activity is disclosed for the LMAT insider?

The insider reported the release of dividend equivalent rights covering 25 shares on 12/11/2025 and 18 shares on two separate entries dated 12/12/2025, all at an exercise price of $0, corresponding to underlying common stock.

Are the share withholdings in this LMAT filing treated as exempt transactions?

The filing notes that the share withholdings to satisfy tax obligations upon vesting of restricted stock units and performance stock units are considered exempt sales under Rule 16b-3(e) under the Securities Exchange Act of 1934.